C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.530
-0.120 (-4.53%)
At close: Nov 17, 2026, 4:00 PM EST
2.520
-0.010 (-0.40%)
After-hours: Nov 17, 2026, 7:41 PM EST

C4 Therapeutics Statistics

Total Valuation

C4 Therapeutics has a market cap or net worth of $332.23 million. The enterprise value is $112.79 million.

Market Cap332.23M
Enterprise Value 112.79M

Important Dates

The last earnings date was Thursday, November 5, 2026, before market open.

Earnings Date Nov 5, 2026
Ex-Dividend Date n/a

Share Statistics

C4 Therapeutics has 131.32 million shares outstanding. The number of shares has increased by 78.97% in one year.

Current Share Class 131.32M
Shares Outstanding 131.32M
Shares Change (YoY) +78.97%
Shares Change (QoQ) +4.12%
Owned by Insiders (%) 0.92%
Owned by Institutions (%) 93.35%
Float 100.55M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 10.27
Forward PS 15.98
PB Ratio 1.45
P/TBV Ratio 1.45
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 3.47
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 5.17, with a Debt / Equity ratio of 0.24.

Current Ratio 5.17
Quick Ratio 4.99
Debt / Equity 0.24
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -47.62% and return on invested capital (ROIC) is -25.52%.

Return on Equity (ROE) -47.62%
Return on Assets (ROA) -21.34%
Return on Invested Capital (ROIC) -25.52%
Return on Capital Employed (ROCE) -35.11%
Weighted Average Cost of Capital (WACC) 18.53%
Revenue Per Employee $310,356
Profits Per Employee -$875,894
Employee Count104
Asset Turnover 0.11
Inventory Turnover n/a

Taxes

In the past 12 months, C4 Therapeutics has paid $121,000 in taxes.

Income Tax 121,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +2.43% in the last 52 weeks. The beta is 3.16, so C4 Therapeutics's price volatility has been higher than the market average.

Beta (5Y) 3.16
52-Week Price Change +2.43%
50-Day Moving Average 3.09
200-Day Moving Average 3.26
Relative Strength Index (RSI) 33.44
Average Volume (20 Days) 3,066,367

Short Selling Information

The latest short interest is 46.58 million, so 35.47% of the outstanding shares have been sold short.

Short Interest 46.58M
Short Previous Month 42.72M
Short % of Shares Out 35.47%
Short % of Float 46.33%
Short Ratio (days to cover) 16.47

Income Statement

In the last 12 months, C4 Therapeutics had revenue of $32.28 million and -$91.09 million in losses. Loss per share was -$0.71.

Revenue32.28M
Gross Profit 28.68M
Operating Income -101.95M
Pretax Income -90.97M
Net Income -91.09M
EBITDA -100.51M
EBIT -101.95M
Loss Per Share -$0.71
Full Income Statement

Balance Sheet

The company has $274.69 million in cash and investments and $55.25 million in debt, with a net cash position of $219.44 million or $1.67 per share.

Cash & Investments 274.69M
Total Debt 55.25M
Net Cash 219.44M
Net Cash Per Share $1.67
Equity (Book Value) 228.17M
Book Value Per Share 1.74
Working Capital 173.04M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$79.63 million and capital expenditures -$112,000, giving a free cash flow of -$79.74 million.

Operating Cash Flow -79.63M
Capital Expenditures -112,000
Depreciation & Amortization 1.44M
Net Borrowing n/a
Free Cash Flow -79.74M
FCF Per Share -$0.61
Full Cash Flow Statement

Margins

Gross margin is 88.85%, with operating and profit margins of -315.86% and -282.22%.

Gross Margin 88.85%
Operating Margin -315.86%
Pretax Margin -281.85%
Profit Margin -282.22%
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

C4 Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -78.97%
Shareholder Yield -78.97%
Earnings Yield -28.23%
FCF Yield -24.05%

Analyst Forecast

The average price target for C4 Therapeutics is $12.50, which is 394.07% higher than the current price. The consensus rating is "Strong Buy".

Price Target $12.50
Price Target Difference 394.07%
Analyst Consensus Strong Buy
Analyst Count 9
Revenue Growth Forecast (3Y) -14.52%
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

C4 Therapeutics has an Altman Z-Score of -1.89 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -1.89
Piotroski F-Score 3